Loading...
•
Dec 31, 2020
Nektar Q4 2020 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2020.
Key Takeaways
Nektar Therapeutics reported Q4 2020 revenue of $23.5 million compared to $33.9 million in Q4 2019. The net loss for the quarter was $117.2 million, or $0.65 loss per share, compared to a net loss of $112.2 million, or $0.64 loss per share in Q4 2019.
Advanced clinical pipeline of novel cytokine therapeutics.
Registrational program evaluating bempegaldesleukin (BEMPEG) plus nivolumab is progressing well with five registrational studies underway.
Added a sixth study to the registrational program to evaluate BEMPEG in combination with pembrolizumab in head and neck cancer.
Early signs of clinical activity for NKTR-255 were reported, advancing two Phase 1 clinical studies in combination with ADCC antibodies.
Nektar
Nektar
Forward Guidance
Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, Thursday, February 25, 2021.